LUPI, ALESSIO
 Distribuzione geografica
Continente #
NA - Nord America 371
EU - Europa 147
AS - Asia 89
AF - Africa 20
SA - Sud America 18
Continente sconosciuto - Info sul continente non disponibili 1
Totale 646
Nazione #
US - Stati Uniti d'America 366
SG - Singapore 37
RU - Federazione Russa 35
IT - Italia 34
CN - Cina 28
IE - Irlanda 27
SE - Svezia 19
BR - Brasile 16
CI - Costa d'Avorio 15
HK - Hong Kong 12
DE - Germania 10
FI - Finlandia 8
FR - Francia 4
IN - India 4
MA - Marocco 4
AZ - Azerbaigian 3
GB - Regno Unito 3
TR - Turchia 3
BO - Bolivia 2
CA - Canada 2
CZ - Repubblica Ceca 2
HN - Honduras 2
NL - Olanda 2
BD - Bangladesh 1
EU - Europa 1
GR - Grecia 1
MX - Messico 1
PK - Pakistan 1
PL - Polonia 1
TN - Tunisia 1
UA - Ucraina 1
Totale 646
Città #
Des Moines 76
Chandler 64
New York 28
Boardman 25
Dublin 25
Singapore 24
Ashburn 23
Abidjan 15
Fairfield 15
Hong Kong 12
Turin 10
Munich 8
The Dalles 8
Lawrence 7
Moscow 7
Princeton 7
Turku 7
Wilmington 6
San Mateo 5
Santa Clara 5
Washington 5
Arnold 4
Pune 4
San Diego 4
Seattle 4
Baku 3
Beijing 3
Woodbridge 3
Ancona 2
Ann Arbor 2
Cambridge 2
El Progreso 2
Fabriano 2
Guangzhou 2
La Paz 2
Los Angeles 2
Olomouc 2
São Paulo 2
Wuhan 2
Andover 1
Ankara 1
Atlanta 1
Boqueirão 1
Centro 1
Changping 1
Chicago 1
Chongqing 1
Dallas 1
Denver 1
Dhaka 1
Fermignano 1
Foshan 1
Gaziantep 1
Goiânia 1
Helsinki 1
Houston 1
Islamabad 1
Islington 1
Itapevi 1
Ituiutaba 1
Jaboatão dos Guararapes 1
Jales 1
Jinan 1
Manchester 1
Mantova 1
Mexico City 1
Milan 1
Minneapolis 1
Montes Claros 1
Morrinhos 1
Naples 1
Nova Iguaçu 1
Nuremberg 1
Odesa 1
Palhoça 1
Parobé 1
Philadelphia 1
Quanzhou 1
Rio de Janeiro 1
Rondonópolis 1
Shanghai 1
Shenzhen 1
Somerville 1
Tavares 1
Tolentino 1
Toronto 1
Tunis 1
Warsaw 1
Wuxi 1
Totale 479
Nome #
The Gustave Roussy Immune (GRIm)-Score Variation Is an Early-on-Treatment Biomarker of Outcome in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Treated with First-Line Pembrolizumab 86
Systemic immune-inflammation index: a prognostic tiebreaker among all in advanced pancreatic cancer 78
Liquid Biopsy-Driven Cetuximab Rechallenge Strategy in Molecularly Selected Metastatic Colorectal Cancer Patients 78
Tumor burden as possible biomarker of outcome in advanced NSCLC patients treated with immunotherapy: a single center, retrospective, real-world analysis 74
Seroprevalence of SARS-CoV-2-Specific Antibodies in Cancer Patients Undergoing Active Systemic Treatment: A Single-Center Experience from the Marche Region, Italy 73
Beyond Microsatellite Instability: Evolving Strategies Integrating Immunotherapy for Microsatellite Stable Colorectal Cancer 72
Retrospective Comparative Analysis of KRAS G12C vs. Other KRAS Mutations in mCRC Patients Treated With First-Line Chemotherapy Doublet + Bevacizumab 51
Hemoglobin and Neutrophil Count as Prognostic Factors in Cholangiocarcinoma Patients in 2nd Line Treatment Setting: Results from a Small Monocentric Retrospective Study 42
Influence of antidiabetic drugs on glucose metabolism and immune response in patients with metastatic pancreatic ductal adenocarcinoma receiving gemcitabine plus nab-paclitaxel as first-line treatment 37
The Landscape of ALK-Rearranged Non-Small Cell Lung Cancer: A Comprehensive Review of Clinicopathologic, Genomic Characteristics, and Therapeutic Perspectives 31
Safety of extended interval dosing immune checkpoint inhibitors: a multicenter cohort study 25
Current Evidence and Future Perspectives about the Role of PARP Inhibitors in the Treatment of Thoracic Cancers 25
Totale 672
Categoria #
all - tutte 4.820
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 4.820


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202123 0 0 0 0 0 0 0 0 5 0 12 6
2021/202259 0 5 0 3 0 5 1 0 14 2 14 15
2022/2023232 13 23 8 15 6 90 0 9 35 6 24 3
2023/2024126 19 4 8 6 16 50 1 3 0 4 1 14
2024/2025232 44 23 4 9 14 13 9 7 43 13 47 6
Totale 672